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ABSTRACT
The emergence of bone as an endocrine regulator has prompted a
re-evaluation of the role of bone mineralization factors in the
development of metabolic disease. Ectonucleotide pyrophosphatase/
phosphodiesterase-1 (NPP1) controls bone mineralization through
the generation of pyrophosphate, and levels of NPP1 are elevated
both in dermal fibroblast cultures and muscle of individuals with
insulin resistance. We investigated the metabolic phenotype
associated with impaired bone metabolism in mice lacking the gene
that encodes NPP1 (Enpp1−/− mice). Enpp1−/− mice exhibited mildly
improved glucose homeostasis on a normal diet but showed a
pronounced resistance to obesity and insulin resistance in response
to chronic high-fat feeding. Enpp1−/− mice had increased levels of the
insulin-sensitizing bone-derived hormone osteocalcin but unchanged
insulin signalling within osteoblasts. A fuller understanding of the
pathways of NPP1 could inform the development of novel therapeutic
strategies for treating insulin resistance.
KEY WORDS: NPP1, Mineralization, Obesity, Diabetes
INTRODUCTION
Bone remodelling is a highly conserved and regulated process that
controls bone homeostasis and maintains skeletal structural integrity.
This vital function is characterized by alternating phases of bone
resorption by osteoclasts and bone formation by osteoblasts, and has
a high energetic cost (Ducy et al., 2000). It has recently been
proposed that insulin signalling mediates communication between
bone remodelling and metabolic control (Ferron et al., 2010a;
Fulzele et al., 2007; Lee et al., 2007). Osteocalcin, a secreted protein
that is specifically expressed in osteoblasts, is essential for this
function of the skeleton. Hormonally active osteocalcin (in an under-
or un-carboxylated form) acts to increase β-cell proliferation, insulin
secretion, peripheral insulin sensitivity and energy expenditure
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(Ferron et al., 2008; Fulzele et al., 2010). This raises the possibility
that other factors controlling bone remodelling impact upon
metabolic homeostasis.
Ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1), also
known as plasma cell membrane glycoprotein 1 (PC-1), is the
founding member of the NPP family – a family consisting of seven
isozymes with a structurally related catalytic domain. The NPPs
hydrolyze phosphodiester or pyrophosphate bonds in various
substrates, including nucleoside triphosphates, lysophospholipids and
choline phosphate esters (Bollen et al., 2000; Stefan et al., 2005;
Zimmermann et al., 2012). NPP1 is a glycoprotein that forms
disulphide-bonded homodimers in both the plasma membrane and
mineral-depositing matrix vesicles of osteoblasts and chondrocytes
(Hessle et al., 2002; Johnson et al., 2001; Terkeltaub, 2006;
Vaingankar et al., 2004). NPP1 hydrolyzes extracellular nucleotides
into inorganic pyrophosphate (PPi), a potent inhibitor of
hydroxyapatite (HA) crystal formation in mineralization-competent
tissues (Terkeltaub, 2001). Mice lacking NPP1 (Enpp1−/−) have severe
mineralization defects, which are associated with abnormally low PPi
levels (Anderson et al., 2005; Johnson et al., 2003; Sali et al., 1999).
Phenotypic features of Enpp1−/− mice include marked alterations in
the mineralization of long bones and calvaria, and pathologic
calcification of the perispinal soft tissue and medial arterial layer
(Mackenzie et al., 2012a; Mackenzie et al., 2012b; Sali et al., 1999).
Impaired insulin action (insulin resistance) is a key risk factor for
type 2 diabetes (DeFronzo, 1988). NPP1 negatively modulates insulin
receptor signalling and has been proposed as a pathogenic factor
predisposing to insulin resistance (Goldfine et al., 2008; Prudente et
al., 2009). ENPP1 is overexpressed in skeletal muscle, adipose tissue,
fibroblasts and lymphocytes of insulin-resistant individuals (Frittitta
et al., 1997; Frittitta et al., 1998; Goldfine et al., 2008; Stentz and
Kitabchi, 2007; Teno et al., 1999). Additionally, overexpression of
NPP1 in cultured cells inhibits insulin receptor autophosphorylation
and downstream signalling (Grupe et al., 1995). Further studies have
shown that NPP1 binds to insulin receptor and inhibits the insulin-
induced conformational changes that lead to insulin receptor
autophosphorylation and tyrosine kinase activation (Maddux et al.,
1995; Maddux and Goldfine, 2000). Studies on the NPP1 Lys121Gln
(K121Q) polymorphism (Pizzuti et al., 1999), a putative genetic
determinant of human insulin resistance, lent further support to NPP1
having a role in the etiology of human insulin resistance. In vitro
studies have provided evidence for the increased susceptibility to
insulin resistance of the Gln121 variant (Di Paola et al., 2011), with
a Lys121Gln meta-analysis conducted on a European population
showing a modest increase of the Gln allele in those at risk of type 2
diabetes (McAteer et al., 2008).
Despite the recognized importance of NPP1 in the control of bone
mineralization, its contribution to the regulation of glucose
metabolism is less clear. Given that elevated NPP1 is associated
with insulin resistance (Goldfine et al., 2008; Prudente et al., 2009),
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we hypothesized that ENPP1 gene deletion would promote
improved glucose homeostasis in the context of obesity-associated
diabetes. To test this we challenged Enpp1−/− mice with chronic
exposure to a high-fat diet (HFD).
RESULTS
Enpp1−/− mice show unaltered fat mass on control diet
There was no significant difference in body weight gain from 4 weeks
of age between wild-type (WT) and Enpp1−/− mice (Fig. 1A), yet a
significant reduction in quadratus femoris muscle mass was observed
from 4 weeks of age in Enpp1−/− mice (12%; P<0.05; Fig. 1B) with
no differences in soleus muscle (Fig. 1C). The loss of muscle mass in
the quadratus femoris, a key target of exercise loading, is a likely
consequence of the debilitating arthritis that the Enpp1−/− mice exhibit
(Filippin et al., 2013). No effect of genotype on food intake was noted.
To assess the onset and severity of arthritis, stride length was assessed
using walking gait analysis. From 6 weeks of age, the stride length of
the Enpp1−/− mice was significantly reduced (P<0.05), as was the
progressive increase in stride length with advancing age (Fig. 1D). No
differences in mRNA expression of muscle genes such as Mstn,
Fbxo32 or Fndc5 were noted in these muscles (data not shown).
There were no differences in white (gonadal, subcutaneous and
mesenteric) or brown fat mass (Fig. 1E), and no changes in mRNA
levels of key genes for adipogenesis (Pparg), lipolysis (Prkaa20),
mitochondrial metabolism (Cpt1a) or glucose transport (Slc2a4) in
gonadal or brown fat mass (data not shown). However, Cpt1a and
Slc2a4 mRNA expression in the subcutaneous fat mass was
significantly reduced in Enpp1−/− mice compared with WT (50%;
P<0.05; Fig. 1F).
Chronic deficiency of NPP1 in mice induces insulin
sensitization on control diet
Owing to the recognized inhibitory activity of NPP1 on the insulin
receptor (Maddux and Goldfine, 2000), we tested whether global
deletion of Enpp1 would translate into changes in whole-body
glucose metabolism. Adult Enpp1−/− mice showed normal glucose
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TRANSLATIONAL IMPACT
Clinical issue
More than half a billion individuals worldwide suffer from obesity, which
is often associated with other metabolic diseases, such as type 2
diabetes. The emergence of bone as an endocrine regulator has led to
the re-evaluation of the role of bone mineralization factors in the
development of metabolic disease. Despite the recognized importance
of ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) in the
regulation of bone mineralization, its contribution to obesity and type 2
diabetes remains less clear.
Results
This research investigates the metabolic phenotype associated with
impaired bone metabolism in mice that lack the gene encoding NPP1
(Enpp1–/– mice). New evidence is provided showing that Enpp1–/– mice
have a pronounced resistance to obesity and to the development of
insulin resistance in response to chronic high-fat feeding. Furthermore,
the authors show that Enpp1–/– mice have increased levels of the insulin-
sensitizing bone-derived hormone osteocalcin, although insulin signalling
remained unchanged within osteoblasts (cells involved in bone
formation) in these mice.
Implications and future directions
These findings shed light on the important role of NPP1 in the
development of obesity and type 2 diabetes, and provide new insights
into the mechanism by which this protein regulates insulin sensitivity. A
deeper understanding of the pathways that are regulated by NPP1 might
advance the development of novel therapeutic strategies for treating
insulin resistance.
Fig. 1. Enpp1−/− mice have significant muscle reduction but not significant changes in fat mass. (A) Body weight (g) growth curves for Enpp1−/− and WT
mice (n=6). (B,C) Enpp1−/− mice show (B) reduced quadratus femoris and (C) unaltered soleus muscle weight relative to total body weight (mg/g), compared
with WT controls (n=6). (D) Walking gait stride length of Enpp1−/− and WT mice (n=4). (E) Subcutaneous, mesenteric, gonadal and brown fat pad weight
relative to total body weight (mg/g) compared with WT controls (n=6). (F) Relative expression of WAT markers and Insr in the subcutaneous fat pad. Mice were
reared under control dietary conditions and were 18 weeks of age at the time of dissection. Results are presented as mean±s.e.m. *P<0.05, ***P<0.001. D
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tolerance tests (GTTs) (Fig. 2A,D) but with a lower glucose-
stimulated insulin secretion (GSIS) peak across the GTT, indicating
insulin sensitization (Fig. 2B,D). Adult Enpp1−/− mice also showed
normal insulin tolerance tests (ITTs) (Fig. 2C,D) and there were no
differences in the size or number of insulin-secreting islets in the
pancreas of Enpp1−/− mice compared with WT (Fig. 3E,F).
Enpp1−/− mice show obesity resistance and improved insulin
tolerance in response to chronic HFD challenge
Chronic high-fat feeding caused weight gain in WT mice, but
Enpp1−/− mice showed resistance to this (Fig. 4A,B). Of note,
quadratus femoris mass increased with a HFD in the Enpp1−/− mice
(40% increase compared with control diet; P<0.05), whereas
walking gait, as denoted by stride length, remained significantly
reduced (P<0.05) (Fig. 4C).
Enpp1−/− mice showed reduced white adipose tissue (WAT) mass
(P<0.01; Fig. 4D) and adipocyte cell diameter (Fig. 4E) compared
with WT. Conversely, a marked increase in brown fat mass (37%;
P<0.001; Fig. 4F) was noted. The gonadal fat pad showed a
significant increase in PGC1α and Fndc5 expression (Fig. 4H),
which are indicative of increased mitochondrial biogenesis.
However, there was no change in Ucp1 mRNA levels (Fig. 4H) and
hence no evidence for increased canonical thermogenesis or white
fat browning as a mechanism underlying the reduced adiposity and
improved metabolic profiles. In WAT, expression of white fat
markers (e.g. Cpt1, Prkaa2) remained unaltered between WT and
Enpp1−/− mice with a HFD (Fig. 4G,H). Moreover, microvesicular
fat in the liver, as detected by Oil Red O staining, was notably
reduced in Enpp1−/− mice in comparison to WT littermates (Fig. 4I).
No gross effect of HFD challenge was seen on kidney, brain,
cardiovascular or muscle tissue architecture in either genotype.
Glucose tolerance was comparable between genotypes
(Fig. 3A,D). However, the insulin level (GSIS) across the GTT was
lower in Enpp1−/− mice, indicating potential insulin sensitization
(Fig. 3B,D). Improved Enpp1−/− insulin sensitivity was confirmed
by an ITT (Fig. 3C,D). Compared with wild-type control mice, no
significant differences in the size or number of insulin-secreting
islets were observed in the pancreas of Enpp1−/− mice (Fig. 3E,F).
Do osteoblasts regulate insulin sensitivity in Enpp1−/− mice?
Given that NPP1 is a negative regulator of insulin signalling, we
investigated whether osteoblast insulin signalling might link NPP1
deficiency and improved whole-body glucose homeostasis. Initially,
we considered the distribution (Fig. 5A) and mRNA expression
(Fig. 5B) of the insulin receptor in confluent monolayers of primary
calvarial osteoblasts, with no effect of genotype observed.
Furthermore there was no effect of NPP1 deletion on insulin-
stimulated Akt, Erk1/2 or GSK3β phosphorylation between
Enpp1−/− and WT primary calvarial osteoblasts cultured in vitro
(Fig. 5C). However, at 12 weeks of age, Enpp1−/− mice exhibited
increased concentrations of the osteoblast-derived insulin-sensitizing
hormone undercarboxylated (GLU13) (119%, P<0.05; Fig. 5D) and
uncarboxylated (GLU) (156%, P<0.05; Fig. 5E) osteocalcin,
whereas carboxylated (GLA13) and total osteocalcin levels were
1343
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Fig. 2. Enpp1−/− mice exhibit insulin sensitization. (A) Glucose tolerance test (GTT). (B) Glucose-stimulated insulin secretion (GSIS). (C) Insulin tolerance
test (ITT) represented as percentage (%) of basal glucose. (D) Metabolic tests analyzed as area under the curve. Mice were reared under control dietary
conditions to 16 weeks of age. Results are presented as mean±s.e.m. (n=8). *P<0.05.
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comparable to WT (Fig. 5F,G). Additionally, the degree of
osteoblast and osteoclast activity was assessed by ELISA analysis
of serum from Enpp1−/− and WT mice. No changes in the bone-
formation marker P1NP were noted (Fig. 5H), whereas a significant
increase in the bone-resorption marker CTx was observed in
Enpp1−/− mice compared with WT controls (P<0.05; Fig. 5I).
Together, these data suggest that the increase in undercarboxylated
osteocalcin detected in Enpp1−/− mice as a result of increased bone
resorption might induce the phenotype of increased insulin-
sensitivity observed.
Chronic HFD challenge induces brittle-bone formation in WT
mice and exacerbates the bone phenotype of Enpp1−/− mice
Given the detrimental effects of obesity on bone (Leslie et al., 2012),
we next considered the effects of chronic high-fat challenge on the
bone physiology of Enpp1−/− mice. Following a chronic HFD
challenge, trabecular bone in WT mice showed a significantly
altered microarchitecture resulting in thinner and more disorganized
trabeculi, compared with mice reared on a control diet (Table 1).
Cortical bone in WT mice fed a HFD showed a significantly
increased bone mineral density (BMD) compared with mice reared
on a control diet (P<0.01). However, cortical thickness was
unchanged by the HFD, resulting in a more brittle bone as
determined by the significantly decreased work to fracture (P<0.05)
and post-failure work (P<0.05) observed in the three-point bending
analysis (work is defined as the necessary force to cause a
displacement and is calculated as the area under the curve) (Table 1).
Enpp1−/− mice displayed a significant deterioration of the already
compromised trabecular architecture following a chronic HFD
challenge, as exemplified by the significant loss of connectivity
indicated by the trabecular pattern factor, the loss of trabecular bone
as measured by percentage of bone volume (BV/TV) and the
reduced trabecular organization when compared with control-diet
mice (Table 1 and Fig. 6A-D). The tibiae of Enpp1−/− mice
displayed a significantly reduced cortical thickness (10%; P<0.01).
This also translated into a weaker, more brittle bone as measured by
three-point bending parameters whereby the work to fracture and
post-failure was significantly reduced by 34% and 50%, respectively
(P<0.05; Table 1). A HFD challenge also induced a significant
decrease in bone modelling in Enpp1−/− mice, as indicated by the
significant reduction in P1NP as a marker of bone formation (38%;
P<0.001; Fig. 6E) and CTx as a marker of bone resorption (20%;
P<0.001; Fig. 6F). These unique data highlight that a chronic high-
fat challenge has crucial effects on the severity of the Enpp1−/− bone
phenotype.
DISCUSSION
The role of NPP1 in controlling the pace of bone mineralization has
been firmly established through the study of in vivo mouse models.
This enzyme is crucial for the regulation of bone mineralization
through the generation of PPi from nucleotide precursors. Enpp1−/−
mice display a distinct phenotype, including reduced long-bone and
increased calvarial mineralization, and pathologic soft-tissue
calcification (Mackenzie et al., 2012a; Mackenzie et al., 2012b; Sali
et al., 1999). The necessity of NPP1 for physiological skeletal
mineralization combined with the considerable evidence linking NPP1
expression with insulin resistance (Bacci et al., 2007; Baratta et al.,
2008; Chandalia et al., 2012; González-Sánchez et al., 2008; Harmey
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Fig. 3. Enpp1−/− mice show improved insulin tolerance in response to a chronic HFD challenge. (A) Glucose tolerance test (GTT). (B) Glucose-
stimulated insulin secretion (GSIS). (C) Insulin tolerance test (ITT) represented as percentage (%) of basal glucose. Mice were reared under high-fat dietary
conditions and were 16 weeks of age. Results are presented as mean±s.e.m. (n=7). *P<0.05. (D) Metabolic tests analyzed as area under the curve.
(E) Number of islets. (F) Size of islets. Results are presented as mean±s.e.m. *P<0.05.
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et al., 2004) led us to investigate whether NPP1 has a functional role
in bone as a newly identified regulator of energy metabolism.
In the present study we have examined the full impact of chronic
suppression of NPP1 and provide new evidence demonstrating that
ablation of the bone mineralization inhibitor NPP1 protects against
insulin resistance, obesity and diabetes. Enpp1−/− mice exhibited
insulin sensitization and, in response to a chronic HFD challenge,
displayed improved insulin tolerance and pronounced obesity
resistance. These novel data extend recent in vitro studies where the
suppression of NPP1 expression in liver, skeletal muscle and
pancreatic β-cells improved insulin sensitivity (Di Paola et al.,
2011). The observation of enhanced insulin sensitivity following
adenoviral knockdown of liver NPP1 expression in a mouse model
of diabetes (db/db; Lepr−/−) further supports our findings (Zhou et
al., 2009). In comparison with db/db mice treated with a control
virus, db/db mice treated with the Enpp1-shRNA adenovirus had
80% lower hepatic Enpp1 mRNA levels, 25% lower fasting plasma
glucose and significantly improved glucose tolerance. This crucial
paper (Zhou et al., 2009) highlights the bone-independent effects of
NPP1 and, together with our findings, supports the proposition that
NPP1 inhibition is a potential therapeutic approach for the treatment
of type 2 diabetes.
The present study provides the first demonstration of an
association between osteocalcin carboxylation status and NPP1.
Enpp1−/− mice presented with increased levels of undercarboxylated
osteocalcin and the bone-resorption marker CTx. These data support
recent findings indicating that insulin signalling in osteoblasts
favours bone resorption by osteoclasts, with decarboxylation of
osteocalcin occurring in resorption lacunae, resulting in increased
circulating undercarboxylated osteocalcin and a positive feedback
loop on insulin secretion (Ferron et al., 2010a; Lacombe et al.,
2013). However, our studies undertaken in calvarial osteoblast
cultures did not reveal a role for NPP1 as a modulator of insulin
signalling in osteoblasts in vitro, suggesting that this model might
not fully reflect osteoblast activity in vivo. Further studies involving
the specific knockout of the insulin receptor in Enpp1−/− osteoblasts
are therefore required to categorically confirm these data. Given the
recent important observation that osteoclasts regulate energy
metabolism (Lacombe et al., 2013), it is also vital to determine
whether Enpp1−/− osteoclasts show any functional defects.
The distinct phenotype of the Enpp1−/− mouse might also directly
influence the metabolic parameters observed in the present study.
Enpp1−/− mice showed reduced body weight, decreased stride length
and significant muscle reduction. These data are highly compatible
1345
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.017905
Fig. 4. Enpp1−/− mice show pronounced obesity resistance in response to a chronic HFD challenge. Enpp1−/− and WT mice were reared on a HFD from
4 weeks of age. (A) Body weight (g) growth curves (n=16). (B) Body weight (g) at 18 weeks of age (n=8). (C) Walking gait stride length in WT and Enpp1−/−
mice (n=4). (D) WAT weight analysis as a ratio to total body weight (mg/g) (n=8). (E) Maximum gonadal fat cell diameter (n=4). (F) BAT weight analysis as a
ratio to total body weight (n=8). (G,H) Gene expression of WAT and BAT markers and Insr in (G) subcutaneous and (H) gonadal fat pad. (I) Histological Oil Red
O staining of lipid deposits in cryosections of the liver. Mice were analyzed at 18 weeks of age after 14 weeks under high-fat dietary conditions. Results are
presented as mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001, NS: non-significant.
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with the observed osteoarthritic phenotype (Mackenzie et al., 2012a;
Sali et al., 1999), which might modulate the insulin sensitization
induced by NPP1 loss. Indeed, metabolic osteoarthritis (OA) has
now been characterized as a subtype of OA, and has been
highlighted as a new facet of the definition of metabolic syndrome,
supported by its strong associations and shared mechanisms with
other metabolic syndrome components (Zhuo et al., 2012). Further
research, however, is needed to define the reciprocal influence of
OA on the currently accepted components of metabolic syndrome,
and the putative role of NPP1.
The insulin-sensitized phenotype observed in the Enpp1−/− mice
might be a direct consequence of NPP1 ablation in insulin-sensitive
tissues such as liver, adipose and skeletal muscle. Overexpression of
NPP1 in liver and muscle induces insulin resistance and
hyperglycemia (Maddux et al., 2006). Moreover, overexpression of
NPP1 in adipocytes leads to adipose insulin resistance, reduction in
fat-cell lipid storage and systemic insulin resistance and glucose
intolerance akin to the effects of lipodystrophy (Pan et al., 2011).
Our data support a beneficial effect of NPP1 deficiency being
manifested potentially through improved insulin sensitivity in liver,
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.017905
Fig. 5. Metabolic effects in
Enpp1−/− mice are independent
of bone insulin signalling but
associated with altered
osteocalcin carboxylation
status. (A) Immunofluorescent
staining of the insulin receptor
(green) on the surface of WT and
Enpp1−/− neonatal calvarial primary
osteoblast cultures. Nuclei are
shown in blue. (B) Relative mRNA
expression levels of Insr in
calvarial osteoblast cultures (n=6).
(C) Representative immunoblots
demonstrating the effects of insulin
(INS; 10 nM) and IGF-1 (10 nM) on
the phosphorylation of Akt,
glycogen synthase kinase-3 beta
(GSK-3β) and Erk1/2 in calvarial
osteoblast cultures (n≥3). 
(D-I) Measurement of serum 
(D) undercarboxylated osteocalcin, 
(E) uncarboxylated osteocalcin, 
(F) carboxylated osteocalcin, 
(G) total osteocalcin, (H) bone-
formation marker P1NP and (I)
bone-resorption marker CTx-I in 
6- and 12-week-old mice. Results
are presented as mean±s.e.m.
(n=6). *P<0.05.
Table 1. Chronic HFD challenge induces an enhanced deterioration of trabecular bone architecture and exacerbates the disrupted bone
mineralization phenotype of Enpp1−/− mice
Control diet High-fat diet
Parameter WT (n=6) Enpp1−/− (n=6) WT (n=8) Enpp1−/− (n=6)
Trabecular bone
Percentage bone volume 13.05±4.388b 7.70±2.101b 9.10±3.119 5.36±2.556
Trabecular thickness (µm) 50.8±7.5 56.5±6.1b 47.6±3.30 47.6±4.7
Trabecular separation (µm) 214.1±56.2 280.1±50.1 247.5±60.31 289.4±80.9
Trabecular number (µm–1) 0.00266±0.00102 0.00137 ±0.00039a 0.00196±0.0007778 0.00115±0.00060a
Trabecular pattern factor 0.0255±0.0075 0.0338±0.00597a,b 0.0319±0.004003 0.0419±0.0066a,b
Structure model index 2.19±0.56 2.74±0.27a,b 2.38±0.279 2.77±0.34
Degree of anisotropy 2.44±0.29b 2.51±0.15b 2.20±0.201 2.24±0.40
Cortical bone
Bone mineral density (g/cm3) 1.29±0.02b 1.31±0.04 1.34±0.02 1.32±0.02
Cortical thickness (µm) 176.03±15.49 175.61±6.33b 181.35±6.64 157.01±13.00a,b
Cortical porosity (%) 2.14±0.61 1.94±0.44 2.08±0.51 1.99±0.29
Maximum stiffness (N/mm) 54.77±6.06 49.09±3.30a 49.09±3.83 48.66±4.13
Work to failure (N•mm) 3.09±1.12 2.26±0.41 2.26±0.44 2.33±0.75
Work to fracture (N•mm) 9.21±2.44b 7.60±1.58a,b 7.60±1.46 4.99±0.10a,b,c
Work post-failure (N•mm) 5.92±1.80b 5.29±1.43a,b 5.29±1.38 2.62±0.72a,b,c
Trabecular bone parameters were measured by µCT on 18-week-old male tibiae. Results are presented as mean±s.d. Significant differences (P<0.05): asame
diet vs WT, bsame genotype vs high-fat diet (HFD). Cortical bone parameters were measured by µCT on 18-week-old male tibiae. The same bones were then
tested for biomechanical properties by 3-point bending. Results are presented as mean±s.d. Significant differences (P<0.05): asame diet vs WT, bsame
genotype vs HFD, cvs different genotype and different diet. D
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muscle and adipose. However, one key difference in the Enpp1−/−
mice is that insulin sensitization is associated with pronounced
reduction in adipose tissue lipid storage without ectopic lipid
accumulation in other organs. This suggests an overarching
beneficial effect of Enpp1 deficiency on energy expenditure that
likely involves other tissues. This could include increased muscle
mitochondrial biogenesis through PGC1-α, a key regulator of energy
metabolism (Ferron et al., 2012) or effects of increased bone
turnover. Tissue-specific ablation of NPP1 is therefore required in
future work to pinpoint the individual tissue(s) driving the metabolic
phenotype of the Enpp1−/− mouse. Furthermore, the association of
the NPP1 K121Q polymorphism with insulin resistance in several
human populations (Baratta et al., 2008; Stolerman et al., 2008)
highlights the need for further studies specifically investigating the
impact of this variant of NPP1 on metabolism. One of the premises
of targeting NPP1 as treatment for type-2-diabetes-induced insulin
resistance is that the inhibition of insulin receptor and NPP1
interactions happens independently of its pyrophosphatase/
phosphodiesterase activity, although the exact mechanism is still
unknown (Chin et al., 2009).
Obesity is linked to normal or higher BMD accompanied by a
paradoxical increase in fracture risk (Leslie et al., 2012). Our
studies mimic this clinical setting of an obesity-induced bone
phenotype in the WT mouse, where the bone is more brittle despite
a higher BMD. Furthermore, our data show that a HFD challenge
induces a decrease in bone modelling that results in an enhanced
deterioration of bone architecture and mechanical properties; this
is even more pronounced in Enpp1−/− mice. This latter observation
might reflect the abnormally low levels of extracellular PPi
observed in these mice, which would result in insufficient PPi
substrate for tissue nonspecific alkaline phosphatase (TNAP) to
generate Pi for normal mineral formation, as previously discussed
(Anderson et al., 2005). Furthermore, an accumulation of
nucleotide triphosphates due to lack of hydrolysis by NPP1
(Prosdocimo et al., 2009) could have a downstream effect on bone
remodelling through purinergic signalling (Orriss et al., 2010). No
differences in cortical porosity were seen between either genotype
or diet; however, it was not possible to distinguish between
vascularity, osteocyte lacunae and areas of non-mineralized matrix
at the resolution examined. Further investigations specifically
examining these individual components using nano-CT would
therefore be of great interest.
In conclusion, our data adds to the body of evidence (Goldfine et
al., 2008; Prudente et al., 2009) supporting NPP1 deficiency as
being protective against insulin resistance. We demonstrate for the
first time that ablation of NPP1 alters osteocalcin carboxylation
status, while protecting against obesity and diabetes (Fig. 7). A fuller
understanding of the pathways of NPP1 could advance the
development of novel therapeutic strategies for treating insulin
resistance.
MATERIALS AND METHODS
Animal model
The generation and characterization of germline Enpp1−/− mice have been
reported previously (Mackenzie et al., 2012a; Sali et al., 1999).
Heterozygote breeders were used to generate distinct litters. Offspring
carrying the mutant Enpp1 gene were identified by PCR and performed by
Genetyper (Genetyper, NY, USA). Male mice were fed a HFD (58% fat;
DBM Scotland, Broxburn, UK) or control diet (6.2% fat; Harlan
Laboratories, Indianapolis, IN, USA) from 4 weeks of age. Ad libitum food
consumption was monitored for 6 days. Progression of arthritis was assessed
with a non-automated ‘cat-walk’ walking gait test, which measured the
distance between the central pads of two alternating hind footprints
(Parvathy and Masocha, 2013). All animal experiments were approved by
The Roslin Institute’s Animal Users Committee and the animals were
maintained in accordance with UK Home Office guidelines for the care and
use of laboratory animals.
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Fig. 6. HFD induces a deterioration of trabecular bone architecture. (A-D) Representative images of trabecular bone from 18-week-old mice tibiae. (A) WT
control diet. (B) Enpp1−/− control diet. (C) WT HFD. (D) Enpp1−/− HFD. (E) Bone-formation marker P1NP and (F) bone-resorption marker CTx-I in 18-week-old
WT and Enpp1−/− mice. Results are presented as mean±s.e.m. (n=6). *P<0.05, ***P<0.001.
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Glucose and insulin tolerance tests
Juvenile and adult (6- and 16-week-old, respectively) male mice were fasted
for 4 hours and administered 2 mg of D-glucose (Sigma, Poole, UK) per g
of body weight by gavage. 16-week-old male mice were fasted for 4 hours
and administered 0.5 (control diet) or 0.75 (HFD) mU of insulin (Actrapid,
NovoNordisk, Bagsvaerd, Denmark) per g of body weight, whereas 6-week-
old male mice were administered 0.375 mU of insulin per g of body weight
intraperitoneally (i.p.). At 0, 15, 30, 60 and 120 minutes after administration,
blood glucose was measured with an Accu-Chek® Aviva glucose meter
(Roche Diagnostics Ltd, Lewes, UK) and insulin was measured by ELISA
(ChrystalChem, Chicago, IL, USA). To allow for recovery from the tests
before sacrifice, juvenile and adult animals were subsequently sacrificed at
7 and 18 weeks of age, respectively. Tissues, including pancreas, liver,
quadratus femoris, soleus muscle and tibiae as well as brown, subcutaneous,
mesenteric and gonadal fat pads, were collected for histological assessment
and gene expression analysis.
Primary osteoblast cell culture
Primary osteoblasts (pOBs) were isolated in the calvariae of 3- to 5-day-old
WT and Enpp1−/− mice as previously described (Huesa et al., 2010; Staines
et al., 2014). Cells were seeded at a density of 2.5×104/cm2 in multi-well
plates, in growth medium consisting of α-MEM (Invitrogen, Paisley, UK)
supplemented with 10% FBS (Invitrogen) and 1% gentamicin (Invitrogen).
Cells were maintained in 95% air/5% CO2 at 37°C.
Cell signalling immunoblotting
Following confluency, pOBs were cultured for 24 hours in serum-free
medium containing 0.1% BSA. Cells were then either lyzed immediately or
stimulated with insulin (10 nM; Sigma) or IGF-I (10 nM; Sigma) for
10 minutes before lysis. Cells were lysed in RIPA buffer (Invitrogen)
containing ‘phosphatase inhibitor cocktail 2’ (Sigma) and ‘complete’
protease inhibitor cocktail (Roche) according to the manufacturers’
instructions. Immunoblotting was conducted with specific antibodies against
phospho-AktSer473, total Akt, phospho-GSK3βSer9, total GSK3β, phospho-
Erk1/2Thr202/Tyr204 and total Erk1/2 (Cell Signaling, Boston, MA, USA).
Immunoblotting was conducted as previously described (Zhu et al., 2011;
Zhu et al., 2013) and visualized using the enhanced chemiluminescence
(ECL) Western Blotting Detection System (GE Healthcare, Chalfont St
Giles, UK).
RNA extraction and qPCR
Bone and fat tissues were extracted using Qiazol (Qiagen, Valencia, CA,
USA) following standard protocol procedures. All other tissues and cell
cultures were extracted with the RNeasy Qiagen kit following the
manufacturer’s instructions (Qiagen). RNA was quantified and reverse
transcribed as previously described (Mackenzie et al., 2011; Macrae et al.,
2009). All genes were analyzed with the SYBR green detection method
(Roche) using the Stratagene Mx3000P real-time QPCR system (Agilent
Technologies, Santa Clara, CA, USA). All gene expression data were
normalized against Atp5B (Primer Design, Southampton, UK; sequence not
disclosed) in osteoblasts, LRP10 in adipose tissue and Gapdh (Primer
Design; sequence not disclosed) in all other tissues. The control values were
expressed as 1 to indicate a precise fold change value for each gene of
interest. All primer sequences were obtained from the Harvard primer bank
database (http://pga.mgh.harvard.edu/primerbank/index.html; primer
sequences are available on request).
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Fig. 7. Schematic representation of the effects of NPP1 on bone mineralization, obesity and glucose intolerance. NPP1 hydrolyses ATP to generate
pyrophosphate (PPi), which is a key inhibitor of mineralization. Global deletion of Enpp1 results in decreased PPi levels, leading to ectopic calcification of blood
vessels and cartilage. However, in long bones such as tibiae, Enpp1 ablation leads to insufficient PPi substrate for TNAP to generate Pi for normal mineral
formation. On the other hand, decreased PPi might reduce the ratio of OPG to RANKL, resulting in increased bone resorption by osteoclasts (Ribeiro et al.,
2014). The acidic pH (4.5) in resorption lacunae decarboxylates osteocalcin (GLA-OCN) stored in the bone extracellular matrix to generate undercarboxylated
active osteocalcin (GLU13-OCN), which stimulates insulin secretion by the β-cells of the pancreatic islets and promotes insulin sensitivity (Ferron and
Lacombe, 2014). Increased insulin binds to the insulin receptor in osteoblasts and inhibits the expression of OPG, driving osteoclastic bone resorption and the
further release of GLU13-OCN. Increased insulin secretion protects HFD-induced obesity and glucose intolerance, and impacts on insulin-sensitive tissues,
such as muscle and adipose. Additionally, GLU13-OCN can directly stimulate energy consumption in skeletal muscle and adipose tissue and might decrease
lipid accumulation in the liver (Rosen and Motyl, 2010).
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Tissue histology and cell immunofluorescence
Dissected tissues were fixed in 4% paraformaldehyde (PFA) or 10%
phosphate buffered formalin (pH 7.4) and embedded in paraffin wax. 5-
μm sections were stained with hematoxylin and eosin (H&E). Fresh tissues
for lipid staining were collected immediately after euthanasia, snap-frozen
in precooled isopentane and stored at −80°C for less than 1 month.
Cryostat sections (10 μm) were stained routinely for lipid with Oil Red O.
Cells were plated onto glass coverslips, fixed in 4% PFA and
permeabilized with 0.1% Triton X-100 in PBS prior to insulin receptor
immunofluorescent staining following standard protocols (Huesa et al.,
2010).
Measurement of islet number and size
Serial sections were cut through each pancreas at 100-μm intervals, stained
with H&E and scanned with a Nikon CoolScan V (Nikon, Surrey, UK). The
total area of a stained pancreas section was measured along with the number
and size of the islets in that section using ImageJ software (Wayne Rasband,
National Institutes of Health, USA). At least five randomly selected serial
sections were examined per pancreas and three mice were analyzed for each
diet/genotype group.
Micro-computed tomography and mechanical testing of tibiae
Tibiae were dissected and immediately frozen in PBS at −20°C pending
analysis. High-resolution scans with an isotropic voxel size of 5 μm were
acquired with a micro-computed tomography system (μCT, 60 kV, 0.5 mm
aluminium filter, 0.6° rotation, Skyscan 1172, Brukker microCT, Kontich,
Belgium). Scans were reconstructed using NRecon software (Brukker
microCT). For each bone, a 1000 μm section of the metaphysis was taken
for analysis of trabecular bone, using the base of the growth plate as a
standard reference point. A further 1500 μm below the base of the
metaphysis section, a 400 μm section of the mid-diaphysis was scanned for
analysis of cortical structure. Data was analyzed with CtAn software
(Brukker microCT). Cortical porosity was measured in the 2D slice-by-slice
analysis. Binarized objects were identified containing fully enclosed spaces,
and porosity was calculated as the area of those spaces as a percent of the
total area of binarized objects. It should be noted that, for this study, total
porosity is a measurement of all of the space within the cortical bone not
filled by mineral, e.g. a blood vessel canal, a large osteocyte lacuna or a
crack. Mechanical testing of the cortical bone was assessed by 3-point
bending analysis using a Zwick materials testing machine (Zwick A.G.,
Ulm, Germany) with a 50 N loading cell, where the span was set at 5.5 mm
and the cross-head speed was set at 1 mm/min. Data was analyzed as
previously described (Huesa et al., 2011).
Serum measurements
Immediately following euthanasia, blood was obtained from non-fasted 6-
and 12-week-old male mice and serum samples prepared. Total,
carboxylated (GLA), undercarboxylated (GLU13-OCN) and uncarboxylated
(GLU) osteocalcin was measured as previously described (Ferron et al.,
2010b), as well as markers of bone formation (P1NP; IDS, Boldon, UK) and
resorption (CTx; IDS).
Statistics
Standard comparisons between WT and Enpp1−/− mice were analyzed by
unpaired Student’s t-test. Comparisons between genotype and diet were
analyzed with two-way ANOVA. Time course experiments were analyzed
with a repeated measures two-way ANOVA. Analysis was carried out using
SigmaStat 12.0 (Systat Software Inc., London, UK).
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